Table 1 Clinical and hematologic characteristics at diagnosis of 382 study patients with prefibrotic PMF.
From: Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis
Variables | N | Â |
|---|---|---|
Male, n (%) | 382 | 195 (51%) |
Age, years, median (range) | 382 | 57.6 (15.6–91.9) |
Age ≥60 years, n (%) | 382 | 170 (45) |
Previous thrombosis, n (%) | 382 | 65 (17) |
 Arterial | 35 (9) | |
 Venous | 31 (8) | |
Microvascular disturbances, n (%) | 370 | 63 (17) |
Major bleeding, n (%) | 382 | 11 (3) |
Blood values | Â | Â |
 Hemoglobin, g/L, median (5th–95th percentiles) | 376 | 135 (93–159) |
 Hematocrit, %, median (5th–95th percentiles) | 345 | 41.1 (30.6–49.0) |
 Platelet count, ×109/L, median (5th–95th percentiles) | 380 | 700 (130–1481) |
 Leukocyte count, ×109/L, median (5th–95th percentiles) | 378 | 10.0 (5.0–24.1) |
LDH > normal range; n (%) | 300 | 220 (73) |
Bone marrow fibrosis grade, n (%) | 382 | Â |
 0 | 161 (42) | |
 1 | 221 (58) | |
Palpable splenomegaly, n (%) | 382 | 180 (47) |
Spleen size, cm from LCM, n (%) | 382 | Â |
 <5 cm | 42 (11) | |
 6–10 cm | 42 (11) | |
 11–15 cm | 71 (19) | |
 16–20 cm | 44 (12) | |
 >20 cm | 23 (6) | |
CV risk factors (at least 1), n (%) | 360 | 161 (45) |
 History of active/remote smoking | 50 (14) | |
 History of hypertension | 97 (27) | |
 History of diabetes mellitus | 27 (8) | |
 History of hypercholesterolemia | 39 (12) | |
Thrombophilia, n (%) | 153 | Â |
 Inherited | 19a (12) | |
 Acquired | 30a (19) | |
 Negative | 105 (69) | |
 Abnormal cytogenetics, n (%) | 286 | 42 (15) |
